+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Insulin Glulisine"

Mealtime Insulin Market - Global Forecast 2025-2030 - Product Thumbnail Image

Mealtime Insulin Market - Global Forecast 2025-2030

  • Report
  • August 2025
  • 182 Pages
  • Global
From
From
Insulin biosimilars Market Report 2025 - Product Thumbnail Image

Insulin biosimilars Market Report 2025

  • Report
  • September 2025
  • 250 Pages
  • Global
From
Short-Acting Insulin Market Report 2025 - Product Thumbnail Image

Short-Acting Insulin Market Report 2025

  • Report
  • September 2025
  • 250 Pages
  • Global
From
From
Type 1 Diabetes Market Report 2025 - Product Thumbnail Image

Type 1 Diabetes Market Report 2025

  • Report
  • March 2025
  • 200 Pages
  • Global
From
Insulin Drugs Market Report 2025 - Product Thumbnail Image

Insulin Drugs Market Report 2025

  • Report
  • March 2025
  • 175 Pages
  • Global
From
From
From
From
From
From
From
From
From
Loading Indicator

Insulin Glulisine is a fast-acting insulin analog used to treat diabetes mellitus, a metabolic disorder. It is used to control high blood sugar levels in adults and children with type 1 diabetes and adults with type 2 diabetes. It is administered by subcutaneous injection and works by helping the body use glucose for energy. It is also used to treat diabetic ketoacidosis, a serious complication of diabetes. Insulin Glulisine is a part of the Endocrine and Metabolic Disorders Drugs market, which includes drugs used to treat endocrine and metabolic disorders such as diabetes, thyroid disorders, and obesity. These drugs are used to regulate hormones, control blood sugar levels, and reduce the risk of complications associated with metabolic disorders. Companies in the Insulin Glulisine market include Eli Lilly, Novo Nordisk, Sanofi, and Biocon. Show Less Read more